In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate.
The main purpose of this study was to prepare a novel in situ gel system for nasal delivery of MF and study its efficacy on allergic rhinitis model. An ion-activated in situ gel was developed and characterized with gellan gum as a carrier. The system was stable kept at 40+/-2 degrees C for 6 months, and the micrographic results showed that in situ gel was safety without mucosa irritation when given at 20 microg once daily for 1 month to rats with allergic rhinitis. MF in gellan gum produced obviously effect on allergic rhinitis at the doses of 20 microg/body following intranasal administration, and the efficacy was significantly superior to that of the common suspension (P<0.01). The in situ gel system is a promising approach for the intranasal delivery of MF for the therapeutic effects improvement.
Cao
Shi-lei
SL
Department of Pharmaceutics, School of Pharmacy, Fudan University (Fenglin Campus), Shanghai, PR China.
Ren
Xiao-wei
XW
Zhang
Qi-zhi
QZ
Chen
En
E
Xu
Feng
F
Chen
Jun
J
Liu
Li-Chun
LC
Jiang
Xin-guo
XG
D000281:Administration, Intranasal; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000633:toxicity; D001001:Anura; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry; D004355:Drug Stability; D004356:Drug Storage; D005260:Female; D005782:Gels; D008297:Male; D000068656:Mometasone Furoate; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism; D011135:Polysaccharides, Bacterial / Q000737:chemistry*; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D018675:Toxicity Tests
D018926:Anti-Allergic Agents; D004337:Drug Carriers; D005782:Gels; D011135:Polysaccharides, Bacterial; D011244:Pregnadienediols; D000068656:Mometasone Furoate; C048288:gellan gum